Merck and Moderna are advancing their personalized mRNA cancer vaccine toward regulatory submission following positive results from a large Phase 3 trial in melanoma patients. The vaccine, known chemically as intismeran autogene, demonstrated the ability to significantly delay both cancer recurrence and development of metastatic disease in treated patients. The companies are now charting a broader development strategy to test the vaccine across additional cancer types and treatment settings.
The vaccine works by analyzing individual tumors and using an algorithm to identify up to 34 mutant proteins, which are then presented to the immune system. The approach is deployed in combination with Merck’s immunotherapy Keytruda, which has undergone extensive testing over many years. The companies have primarily focused on settings where Keytruda has proven effective, particularly as an add-on therapy for melanoma patients after surgical removal of visible tumors. Ongoing trials are examining the vaccine in adjuvant settings for lung, kidney, and bladder cancer.
Company executives outlined plans to explore additional applications, including use in tumors where Keytruda previously failed but other immunotherapies succeeded, as well as potential deployment as a standalone therapy in early-stage disease. Small tests are underway in adjuvant pancreatic and gastric cancer settings. The companies are also investigating use in patients whose metastatic tumors have been previously reduced through other treatments.
Merck R&D leadership emphasized their strategy centers on tumor types where immunotherapy approaches are known to be effective, contrasting their approach with competitors pursuing cold or metastatic tumors. The companies continue refining the underlying technology by analyzing immune system responses across their trial populations. Executives indicated they have accumulated substantial data from several thousand patients enrolled in their Phase 3 program that could inform algorithmic improvements to vaccine design.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI